ES2332137T3 - Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso. - Google Patents

Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso. Download PDF

Info

Publication number
ES2332137T3
ES2332137T3 ES04767442T ES04767442T ES2332137T3 ES 2332137 T3 ES2332137 T3 ES 2332137T3 ES 04767442 T ES04767442 T ES 04767442T ES 04767442 T ES04767442 T ES 04767442T ES 2332137 T3 ES2332137 T3 ES 2332137T3
Authority
ES
Spain
Prior art keywords
radical
alkyl
representing
amino
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04767442T
Other languages
English (en)
Spanish (es)
Inventor
Gregoire Prevost
Marie-Christine Brezak Pannetier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Application granted granted Critical
Publication of ES2332137T3 publication Critical patent/ES2332137T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES04767442T 2003-06-25 2004-06-24 Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso. Expired - Lifetime ES2332137T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307649 2003-06-25
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX

Publications (1)

Publication Number Publication Date
ES2332137T3 true ES2332137T3 (es) 2010-01-27

Family

ID=33515382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04767442T Expired - Lifetime ES2332137T3 (es) 2003-06-25 2004-06-24 Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso.

Country Status (14)

Country Link
US (3) US20060281736A1 (https=)
EP (3) EP1792905A1 (https=)
JP (2) JP2007514639A (https=)
AR (2) AR044930A1 (https=)
AT (1) ATE439836T1 (https=)
CA (1) CA2530668A1 (https=)
DE (1) DE602004022674D1 (https=)
DK (1) DK1641453T3 (https=)
ES (1) ES2332137T3 (https=)
FR (1) FR2856688B1 (https=)
MX (1) MXPA06000216A (https=)
MY (1) MY141725A (https=)
PL (1) PL1641453T3 (https=)
WO (1) WO2005000852A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
BR0215336A (pt) * 2001-12-27 2004-11-16 Scras Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) * 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2190924B1 (de) * 2007-09-06 2011-05-25 Basf Se Blends aus verzweigten polyarylethern und hydrophilen polymeren
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI421252B (zh) 2009-07-09 2014-01-01 Irm Llc 用於治療寄生蟲疾病之化合物及組合物
ME02395B (me) * 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
TWI791515B (zh) 2017-04-24 2023-02-11 瑞士商諾華公司 治療療法
US20210106567A1 (en) * 2019-10-01 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
JP2023503318A (ja) 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
EP1233787B8 (fr) * 1999-11-09 2005-05-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
EP1345941A1 (fr) * 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
BR0215336A (pt) * 2001-12-27 2004-11-16 Scras Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Also Published As

Publication number Publication date
US20090253685A1 (en) 2009-10-08
WO2005000852A2 (fr) 2005-01-06
US20060281736A1 (en) 2006-12-14
ATE439836T1 (de) 2009-09-15
EP1641453A2 (fr) 2006-04-05
AR044930A1 (es) 2005-10-12
US20090137596A1 (en) 2009-05-28
AR070977A2 (es) 2010-05-19
FR2856688A1 (fr) 2004-12-31
EP1641453B1 (fr) 2009-08-19
DK1641453T3 (da) 2009-12-14
FR2856688B1 (fr) 2008-05-30
WO2005000852A3 (fr) 2005-06-30
EP1792905A1 (fr) 2007-06-06
MY141725A (en) 2010-06-15
JP2009149694A (ja) 2009-07-09
PL1641453T3 (pl) 2010-01-29
EP2335702A1 (fr) 2011-06-22
DE602004022674D1 (de) 2009-10-01
MXPA06000216A (es) 2006-04-11
JP2007514639A (ja) 2007-06-07
CA2530668A1 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
ES2332137T3 (es) Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso.
AU2009231885B2 (en) Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use
ES2505270T3 (es) Inhibidores de JAK2 y su uso para el tratamiento de enfermedades mieloproliferativas y cáncer
AU2009298008B2 (en) Pyrazolo pyridine derivatives as NADPH Oxidase inhibitors
US20090131428A1 (en) Benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
NZ551468A (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
US7495021B2 (en) Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
EP4701635A1 (en) 1,2,4-triazole-3-thione inhibitors of trex2 for use in the treatment of psoriasis, atopic dermatitis or ichthyosis
AU2013231140A1 (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
HK1147741B (en) Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use